2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
10
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
84
Etoposide
31
Daunorubicin
31
Mitoxantrone
26
Idarubicin
26
Filgrastim
24
Busulfan
20
Peripheral Blood Stem Cell Transplantation
19
Cyclophosphamide
17
fludarabine phosphate
15
Gemtuzumab
14
tipifarnib
11
Azacitidine
11
Methotrexate
10
Clofarabine
10
sargramostim
9
Gene Expression Profiling
9
Flow Cytometry
9
Cyclosporine
9
Tacrolimus
8
Radiotherapy
8
Granulocyte Colony-Stimulating Factor
7
Decitabine
7
Antilymphocyte Serum
7
alvocidib
6
Topotecan
6
Bortezomib
6
Arsenic Trioxide
6
valspodar
5
aldesleukin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Monocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn